Literature DB >> 10652425

Expression of emmprin by oral squamous cell carcinoma.

L C Bordador1, X Li, B Toole, B Chen, J Regezi, L Zardi, Y Hu, D M Ramos.   

Abstract

A transmembrane glycoprotein recently identified on some tumor cells, extracellular matrix metalloproteinase inducer (EMMPRIN), has been shown to induce metalloproteinase (MMP) production by peritumor fibroblasts (PTF). We examined biopsy specimens of normal human oral mucosa and oral squamous cell carcinoma (SCC) for expression of EMMPRIN. In normal mucosa, EMMPRIN was expressed at the cell membrane throughout the epithelium with a slight enhancement along the basal cell layer. In oral SCC, EMMPRIN was expressed at the cell membrane throughout the entire lesion. Immunofluorescence microscopy localized EMMPRIN to the cell membrane in a highly invasive oral SCC cell line in agreement with our in vivo observations. Function-blocking antibodies to EMMPRIN significantly inhibited oral SCC cell migration on tenascin-C (TN-C) and fibronectin as well as invasion through a reconstituted basement membrane (RBM). We previously showed that soluble factors from SCC cells and PTF are required for deposition of a TN-C matrix. To determine whether EMMPRIN may modulate the release or expression of these soluble factors, we again used function-blocking antibodies. Antibodies to EMMPRIN completely inhibited the organization of TN-C matrices and partially reduced the deposition of FN matrices by oral SCC cell /PTF co-cultures. In addition, antibodies to EMMPRIN perturbed the expression of MMP-2. Moreover, antibodies to MMP-2 perturbed oral SCC cell invasion of an RBM by approx. 75%. Our results demonstrate that EMMPRIN is highly expressed in oral SCC, facilitates tumor cell motility, and mediates TN-C matrix deposition. Taken together, these results suggest that EMMPRIN may help regulate oral squamous cell carcinoma invasion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652425

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro.

Authors:  Yu Li; Peng Shang; Ai-Rong Qian; Li Wang; Yong Yang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

2.  CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.

Authors:  Yi-Jun Xue; Qiang Lu; Zhi-Xi Sun
Journal:  Med Oncol       Date:  2010-05-28       Impact factor: 3.064

3.  Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma.

Authors:  Shaojun Zhu; Yanhong Li; Li Mi; Yang Zhang; Li Zhang; Li Gong; Xiujuan Han; Li Yao; Miao Lan; Zhinan Chen; Wei Zhang
Journal:  Dig Dis Sci       Date:  2011-07-26       Impact factor: 3.199

4.  CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study.

Authors:  Yau-Hua Yu; Jose Morales; Lei Feng; J Jack Lee; Adel K El-Naggar; Nadarajah Vigneswaran
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-01-07

5.  Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.

Authors:  Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal
Journal:  Mol Cancer Res       Date:  2011-06-10       Impact factor: 5.852

6.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.

Authors:  J Robert Newman; Emily E Helman; Seena Safavy; Wenyue Zhang; Eben L Rosenthal
Journal:  Cancer Lett       Date:  2008-11-05       Impact factor: 8.679

Review 8.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

9.  The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2.

Authors:  Adriana Papadimitropoulou; Avgi Mamalaki
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

10.  Upregulation of EMMPRIN after permanent focal cerebral ischemia.

Authors:  Wei Zhu; Steve Khachi; Qi Hao; Fanxia Shen; William L Young; Guo-Yuan Yang; Yongmei Chen
Journal:  Neurochem Int       Date:  2007-11-26       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.